Dr. Bordoni on the Utility of Adjuvant Atezolizumab in the Adjuvant Setting in NSCLC
Rodolfo Bordoni, MD, discusses the utility of atezolizumab in the adjuvant setting in non–small cell lung cancer.
Dr. Bordoni on the Utility of Adjuvant Osimertinib in EGFR-Mutant Lung Cancer
Rodolfo Bordoni, MD, discusses the utility of adjuvant osimertinib in lung cancer.
Dr. Bardoni on the Importance of the LIBRETTO-001 Trial With Selpercatinib in RET+ NSCLC
Rodolfo Bordoni, MD, discusses the importance of the phase 1/2 LIBRETTO-001 trial with selpercatinib in patients with RET fusion–positive non–small cell lung cancer.
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing
Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC
2 Clarke Drive Cranbury, NJ 08512